Royalty Report: Medical, Therapeutic, Device – Collection: 6556


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Medical
  • Therapeutic
  • Device
  • Chemicals
  • Coating
  • Supply
  • Drugs
  • Disease
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6556

License Grant
Swiss Universities hereby grant Contractor an exclusive, worldwide, perpetual license under their Proprietary Rights in the Technology, without limitation or restriction as to use or field of use.
License Property
The Licensee completed the purchase of the polymer technology assets of a private medical technology company based in the United Kingdom. The assets comprise a series of United States and foreign patent applications as well as scientific and clinical documentation that provide us a second platform technology for future product development. The Licensee also assumed rights and obligations under a development Agreement with the Licensors, as well as with the principal investigator of the technology development project. If the Licensee fails to sublicense the technology or pursue development efforts involving the technology for a period of two years or more, the Licensee is obligated to negotiate a return of the technology to the University.
Field of Use
The Licensee is a biomaterials company engaged in the development and commercialization of innovative and cost-effective medical devices for therapeutic applications.  The products and product candidates, all of which are based on our proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions (scar tissue) following a broad range of surgical procedures.

IPSCIO Record ID: 1670

License Grant
Israeli University has assigned to the Company its worldwide rights to patents, patent applications and know-how to develop, manufacture and market products relating to biomedical polymers technology; preventing or reducing post-operative surgical adhesions; dated June 14, 1991, as amended in February 1994, as of January 1996 and as of October 1996; proprietary bioresorbable polymer technology.
License Property
The Company's bioresorbable polymer technology is based on a proprietary group of polymers.  The Company believes that these polymers display desirable properties, which enable them to be tailored to a wide variety of applications.  These properties include bioresorbability, flexibility, strength and biocompatibility.
Field of Use
Potential applications for products derived from these polymers are in medical areas such as the prevention of post-operative adhesions, sutures, stents, implantable device coatings and drug delivery.

IPSCIO Record ID: 1355

License Grant
The Licensee is party to an Agreement relating to the Polymer Technology with the Licensor, an individual.
License Property
The polymer technology is the core technology of a our business.
Field of Use
The biomaterials Licensee is engaged in the development and commercialization of anti-adhesion products. The company is primarily focused on the commercialization of REPEL-CV(TM) Bioresorbable Adhesion Barrier and the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technologies.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.